HXBM (Helix Biomedix) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


What is Helix Biomedix Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Helix Biomedix's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

HXBM vs XBIO, CBLI, ADYX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Helix Biomedix's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix Biomedix Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix Biomedix's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Helix Biomedix's Margin of Safety % (DCF FCF Based) falls into.


Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.